Here are four things to know about the affiliation.
1. The arrangement means the two organizations can partner on clinical trials and will allow BMC’s physicians to consult Dana-Farber specialists when treating complex cancer cases, according to the report.
2. Under the deal, BMC will pay Dana-Farber a fee and will be able to market itself as a member of the Dana-Farber/Brigham and Women’s Cancer Care Collaborative. As a member, BMC staff will have access to educational opportunities and medical specialists at Dana-Farber/Brigham and Women’s CancerCenter in Boston.
3. Specialists from Dana-Farber and its partner, Boston-based Brigham and Women’s Hospital, evaluated BMC’s cancer programs to ensure they were up to their standards before agreeing to the affiliation, according to The Boston Globe.
4. BMC and Dana-Farber will submit their affiliation plan to the state Health Policy Commission, which reviews hospital deals.
More articles on integration and physician issues:
Family physicians play critical role in ED care in urban hospitals
Harvard Medical School restructures curriculum: 4 things to know
DaVita to acquire Everett Clinic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
